Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CVET Stock Summary
In the News

CD&R, TPG Take Covetrus Private In $4B Deal
Clayton, Dubilier & Rice (CD&R), a private investment firm, and TPG Capital will acquire animal-health technology and services company Covetrus Inc (NASDAQ: CVET) for $21.00 per share, representing an enterprise value of approximately $4 billion. CD&R and its affiliates.

Covetrus going private in $4 billion deal
Animal health company Covetrus Inc. CVET, -0.20% said Wednesday it agreed to be taken private by Clayton, Dubilier & Rice (CD&R) and TPG Capital TPG, -0.90% in a deal valued at $4 billion. The two private equity firms agreed to pay $21 a share, which is $1.34 or 6.8% over its closing price of $19.66 a share on Tuesday and a 39% premium over its 30-day volume weighted average price per share as of the unaffected stock price as of May 13.

Covetrus to Be Taken Private for $4 Billion
Private-equity firms CD&R and TPG Capital will pay $21 a share to acquire the veterinary services company.

Covetrus Gets Private-Equity Buyout Offer at $21 a Share
CD&R and TPG offer to pay $21 a share in cash for Covetrus, which develops technologies and services for the animal health industry.

Covetrus (CVET) Q1 Earnings Surpass Estimates
Covetrus (CVET) delivered earnings and revenue surprises of 8.70% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Covetrus, Inc. (CVET) CEO Ben Wolin on Q4 2021 Results - Earnings Call Transcript
Covetrus, Inc. (CVET) CEO Ben Wolin on Q4 2021 Results - Earnings Call Transcript

Covetrus (CVET) Q4 Earnings Surpass Estimates
Covetrus (CVET) delivered earnings and revenue surprises of 4% and 1.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Covetrus (CVET) Matches Q3 Earnings Estimates
Covetrus (CVET) delivered earnings and revenue surprises of 0.00% and -0.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Covetrus: Q3 Earnings Insights
Covetrus (NASDAQ:CVET) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Covetrus Announces Third Quarter 2021 Earnings Release Date and Conference Call Information
PORTLAND, Maine--(BUSINESS WIRE)---- $CVET #earnings--Covetrus will release Q3 2021 results after the market close on Thursday, November 4, 2021 and the company will hold a conference call at 4:30 PM ET.
CVET Financial details
CVET Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 32.19 | 33.98 | 37.16 | 36.77 | 33.39 | |
Net income per share | 0.58 | 0.91 | -9.52 | -0.16 | -0.39 | |
Operating cash flow per share | 0.97 | 1.42 | 0.96 | 0.45 | 0.74 | |
Free cash flow per share | 0.79 | 1.22 | 0.6 | -0.04 | 0.31 | |
Cash per share | 0.15 | 0.21 | 1.21 | 2.46 | 1.34 | |
Book value per share | 10.91 | 13.43 | 11.74 | 13.03 | 11.03 | |
Tangible book value per share | 2.24 | 4.82 | -5.06 | -1.74 | -1.28 | |
Share holders equity per share | 10.91 | 13.43 | 11.74 | 13.03 | 11.03 | |
Interest debt per share | 0.24 | 0.22 | 11.62 | 9.46 | 7.87 | |
Market cap | 4.67B | 4.67B | 1.41B | 3.39B | 2.74B | |
Enterprise value | 4.68B | 4.67B | 2.47B | 4.17B | 3.6B | |
P/E ratio | 72.57 | 46.3 | -1.39 | -178.49 | -50.66 | |
Price to sales ratio | 1.3 | 1.24 | 0.36 | 0.78 | 0.6 | |
POCF ratio | 43.17 | 29.58 | 13.71 | 63.99 | 26.82 | |
PFCF ratio | 53.36 | 34.37 | 22.07 | -678.26 | 65.14 | |
P/B Ratio | 3.85 | 3.13 | 1.12 | 2.21 | 1.81 | |
PTB ratio | 3.85 | 3.13 | 1.12 | 2.21 | 1.81 | |
EV to sales | 1.31 | 1.24 | 0.62 | 0.96 | 0.79 | |
Enterprise value over EBITDA | 27.3 | 23.12 | -3.11 | 19.76 | 20.22 | |
EV to operating cash flow | 43.26 | 29.58 | 23.97 | 78.69 | 35.28 | |
EV to free cash flow | 53.47 | 34.38 | 38.58 | -834.06 | 85.69 | |
Earnings yield | 0.01 | 0.02 | -0.72 | -0.01 | -0.02 | |
Free cash flow yield | 0.02 | 0.03 | 0.05 | 0 | 0.02 | |
Debt to equity | 0.79 | 0.5 | 1.68 | 1.27 | 1.26 | |
Debt to assets | 0.44 | 0.33 | 0.63 | 0.56 | 0.56 | |
Net debt to EBITDA | 0.06 | 0 | -1.33 | 3.69 | 4.85 | |
Current ratio | 2.11 | 1.9 | 1.62 | 2.07 | 1.94 | |
Interest coverage | 0 | 0 | -17.8 | -1.47 | -0.72 | |
Income quality | 1.68 | 1.57 | -0.1 | -2.79 | -1.89 | |
Dividend Yield | 0 | 0 | 0.83 | 0 | 0 | |
Payout ratio | 0 | 0 | -1.15 | -0.32 | 0 | |
Sales general and administrative to revenue | 0.14 | 0.14 | 0.2 | 0.2 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.44 | 0.43 | 0.53 | 0.5 | 0.49 | |
Capex to operating cash flow | -0.19 | -0.14 | -0.38 | -1.09 | -0.59 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
Capex to depreciation | -0.35 | -0.34 | -0.22 | -0.31 | -0.3 | |
Stock based compensation to revenue | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Graham number | 11.92 | 16.56 | 50.15 | 6.87 | 9.89 | |
ROIC | 0.05 | 0.06 | -0.38 | -0.02 | -0.01 | |
Return on tangible assets | 0.05 | 0.08 | -0.65 | -0.01 | -0.03 | |
Graham Net | -2.64 | -0.67 | -12.03 | -8.25 | -7.36 | |
Working capital | 565.34M | 514.04M | 511M | 740M | 653M | |
Tangible asset value | 249.3M | 535.64M | -541M | -205M | -175M | |
Net current asset value | 121.9M | 347.14M | -765M | -528M | -548M | |
Invested capital | 0.02 | 0.02 | 0.95 | 0.7 | 0.69 | |
Average receivables | 463.6M | 491.76M | 486.5M | 533.5M | 564.5M | |
Average payables | 358.48M | 408.62M | 480.73M | 462.5M | 423.5M | |
Average inventory | 504.16M | 549.41M | 600.08M | 583M | 556.5M | |
Days sales outstanding | 51.34 | 46.37 | 45.26 | 48.29 | 44.28 | |
Days payables outstanding | 46.85 | 52.08 | 58.82 | 41.75 | 43.4 | |
Days of inventory on hand | 66.66 | 66.56 | 71.94 | 54.63 | 57.25 | |
Receivables turnover | 7.11 | 7.87 | 8.06 | 7.56 | 8.24 | |
Payables turnover | 7.79 | 7.01 | 6.21 | 8.74 | 8.41 | |
Inventory turnover | 5.48 | 5.48 | 5.07 | 6.68 | 6.38 | |
ROE | 0.05 | 0.07 | -0.81 | -0.01 | -0.04 | |
Capex per share | -0.19 | -0.2 | -0.36 | -0.49 | -0.44 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 8.68 | 8.48 | 8.13 | 8.32 | 8.69 | |
Net income per share | -0.23 | -0.03 | -0.02 | -0.01 | -0.03 | |
Operating cash flow per share | 0.42 | 0.43 | 0.32 | -0.24 | -0.04 | |
Free cash flow per share | 0.34 | 0.33 | 0.16 | -0.32 | -0.15 | |
Cash per share | 1.68 | 1.36 | 1.33 | 0.85 | 0.62 | |
Book value per share | 10.96 | 10.96 | 10.95 | 11.07 | 10.75 | |
Tangible book value per share | -1.23 | -1.64 | -1.27 | -0.95 | -0.86 | |
Share holders equity per share | 10.96 | 10.96 | 10.95 | 11.07 | 10.75 | |
Interest debt per share | 7.88 | 7.89 | 7.62 | 7.64 | 7.54 | |
Market cap | 3.7B | 2.49B | 2.76B | 2.32B | 2.91B | |
Enterprise value | 4.54B | 3.37B | 3.62B | 3.25B | 3.87B | |
P/E ratio | -29.83 | -155.32 | -229.66 | -289.63 | -181.56 | |
Price to sales ratio | 3.11 | 2.14 | 2.46 | 2.02 | 2.39 | |
POCF ratio | 63.78 | 42.12 | 62.63 | -70.21 | -484.17 | |
PFCF ratio | 78.7 | 55.23 | 125.27 | -52.66 | -138.33 | |
P/B Ratio | 2.46 | 1.65 | 1.82 | 1.52 | 1.93 | |
PTB ratio | 2.46 | 1.65 | 1.82 | 1.52 | 1.93 | |
EV to sales | 3.82 | 2.9 | 3.23 | 2.83 | 3.18 | |
Enterprise value over EBITDA | 100.89 | 78.4 | 77 | 57.98 | 74.37 | |
EV to operating cash flow | 78.28 | 57.14 | 82.25 | -98.39 | -644.5 | |
EV to free cash flow | 96.6 | 74.92 | 164.49 | -73.8 | -184.14 | |
Earnings yield | -0.01 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0.01 | 0.02 | 0.01 | -0.02 | -0.01 | |
Debt to equity | 1.27 | 1.28 | 1.26 | 1.26 | 1.24 | |
Debt to assets | 0.56 | 0.56 | 0.56 | 0.55 | 0.55 | |
Net debt to EBITDA | 18.69 | 20.6 | 18.36 | 16.61 | 18.5 | |
Current ratio | 2 | 1.89 | 1.94 | 1.86 | 1.88 | |
Interest coverage | -1 | -0.5 | -1.17 | 0.86 | 0.57 | |
Income quality | -1.87 | -14.75 | -14.67 | 16.5 | 1.5 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.49 | 0.5 | 0.49 | 0.48 | 0.48 | |
Capex to operating cash flow | -0.19 | -0.24 | -0.5 | 0.33 | 2.5 | |
Capex to revenue | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | |
Capex to depreciation | -0.2 | -0.29 | -0.43 | -0.23 | -0.31 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 7.47 | 2.68 | 2.31 | 1.9 | 2.63 | |
ROIC | -0.01 | 0 | 0 | 0 | 0 | |
Return on tangible assets | -0.02 | 0 | 0 | 0 | 0 | |
Graham Net | -6.98 | -7.51 | -7.31 | -7.38 | -7.13 | |
Working capital | 710M | 637M | 653M | 655M | 645M | |
Tangible asset value | -169M | -224M | -175M | -131M | -121M | |
Net current asset value | -493M | -567M | -548M | -503M | -493M | |
Invested capital | 0.71 | 0.71 | 0.69 | 0.69 | 0.7 | |
Average receivables | 600.5M | 582M | 561.5M | 591M | 641.5M | |
Average payables | 421.5M | 427.5M | 435M | 474.5M | 476.5M | |
Average inventory | 556M | 554.5M | 567.5M | 606.5M | 608.5M | |
Days sales outstanding | 45.11 | 43.99 | 44.52 | 49.16 | 48.51 | |
Days payables outstanding | 39.66 | 40.72 | 43.71 | 49.44 | 40.63 | |
Days of inventory on hand | 51.73 | 52.52 | 57.66 | 61.43 | 53.47 | |
Receivables turnover | 1.99 | 2.05 | 2.02 | 1.83 | 1.86 | |
Payables turnover | 2.27 | 2.21 | 2.06 | 1.82 | 2.22 | |
Inventory turnover | 1.74 | 1.71 | 1.56 | 1.47 | 1.68 | |
ROE | -0.02 | 0 | 0 | 0 | 0 | |
Capex per share | -0.08 | -0.1 | -0.16 | -0.08 | -0.11 |
CVET Frequently Asked Questions
What is Covetrus, Inc. stock symbol ?
Covetrus, Inc. is a US stock , located in Portland of Maine and trading under the symbol CVET
What is Covetrus, Inc. stock quote today ?
Covetrus, Inc. stock price is $- today.
Is Covetrus, Inc. stock public?
Yes, Covetrus, Inc. is a publicly traded company.